✦ LIBER ✦
XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy
✍ Scribed by A del Giglio; A Eniu; D Ganea-Motan; E Topuzov; H Lubenau
- Book ID
- 115011401
- Publisher
- BioMed Central
- Year
- 2008
- Tongue
- English
- Weight
- 385 KB
- Volume
- 8
- Category
- Article
- ISSN
- 1471-2407
No coin nor oath required. For personal study only.